G&E Herbal Biotechnology Co., Ltd. Statistics
G&E Herbal Biotechnology Co., Ltd. (4911) Stock Statistics & Valuation Metrics
Total Valuation
G&E Herbal Biotechnology Co., Ltd. has a market cap or net worth of TWD 1.72B. The enterprise value is TWD 1.78B.
- Market Cap
- TWD 1.72B
- Enterprise Value
- TWD 1.78B
Share Statistics
G&E Herbal Biotechnology Co., Ltd. has 68,817,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 68,817,130
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
G&E Herbal Biotechnology Co., Ltd.’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 14.31%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.14
- Return on Invested Capital (ROIC)
- 14.31%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 8.14M
- Profits Per Employee
- 3.66M
- Employee Count
- 38
- Asset Turnover
- 0.32
- Inventory Turnover
- 1.96
Valuation Ratios
The current PE Ratio of G&E Herbal Biotechnology Co., Ltd. is 18.88. G&E Herbal Biotechnology Co., Ltd.’s PEG ratio is -0.49.
- PE Ratio
- 18.88
- PS Ratio
- 8.08
- PB Ratio
- 2.15
- Price to FCF
- 90.88
- Price to Operating Cash Flow
- 85.04
- PEG Ratio
- -0.49
Income Statement
In the last 12 months, G&E Herbal Biotechnology Co., Ltd. had revenue of 309.13M and earned 139.20M in profits. Earnings per share was 2.18.
- Revenue
- 309.13M
- Gross Profit
- 259.60M
- Operating Income
- 152.30M
- Pretax Income
- 158.39M
- Net Income
- 139.20M
- EBITDA
- 162.91M
- Earnings Per Share (EPS)
- 2.18
Cash Flow
In the last 12 months, operating cash flow was 22.11M and capital expenditures -2.96M, giving a free cash flow of 19.16M billion.
- Operating Cash Flow
- 22.11M
- Free Cash Flow
- 19.16M
- Free Cash Flow per Share
- 0.26
Dividends & Yields
G&E Herbal Biotechnology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 4.66%
- Dividend Per Share
- ―
- Dividend Yield
- 4.66%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.10%
- Earnings Yield
- 4.59%
Stock Price Statistics
- Beta
- 0.16
- 52-Week Price Change
- -43.75%
- 50-Day Moving Average
- 28.15
- 200-Day Moving Average
- 30.17
- Relative Strength Index (RSI)
- 32.28
- Average Volume (3m)
- 21.58K
Important Dates
G&E Herbal Biotechnology Co., Ltd. upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
G&E Herbal Biotechnology Co., Ltd. as a current ratio of 10.09, with Debt / Equity ratio of 0.75%
- Current Ratio
- 10.09
- Quick Ratio
- 9.55
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.44
- Interest Coverage Ratio
- 5251.76
Taxes
In the past 12 months, G&E Herbal Biotechnology Co., Ltd. has paid 19.20M in taxes.
- Income Tax
- 19.20M
- Effective Tax Rate
- 0.12
Enterprise Valuation
G&E Herbal Biotechnology Co., Ltd. EV to EBITDA ratio is 16.97, with an EV/FCF ratio of 83.63.
- EV to Sales
- 7.43
- EV to EBITDA
- 16.97
- EV to Free Cash Flow
- 83.63
- EV to Operating Cash Flow
- 72.46
Balance Sheet
G&E Herbal Biotechnology Co., Ltd. has TWD 425.82M in cash and marketable securities with TWD 5.00M in debt, giving a net cash position of TWD 420.82M billion.
- Cash & Marketable Securities
- TWD 425.82M
- Total Debt
- TWD 5.00M
- Net Cash
- TWD 420.82M
- Net Cash Per Share
- TWD 6.12
- Tangible Book Value Per Share
- TWD 10.01
Margins
Gross margin is 79.24%, with operating margin of 38.46%, and net profit margin of 40.00%.
- Gross Margin
- 79.24%
- Operating Margin
- 38.46%
- Pretax Margin
- 41.40%
- Net Profit Margin
- 40.00%
- EBITDA Margin
- 43.79%
- EBIT Margin
- 38.84%
Analyst Forecast
The average price target for G&E Herbal Biotechnology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -26.73%
- EPS Growth Forecast
- -34.96%
